Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323913 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL2326694 | 0.83 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BADORA3MAPK13 | |
| SCHEMBL23424155 | 0.82 | ADORA2A (0.82) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL20392699 | 0.81 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BADORA3MAPK14 | |
| SCHEMBL28937364 | 0.80 | ADORA1 (0.62) | ADORA2AADORA1ADORA2BADORA3 | |
| Imaradenant SCHEMBL29353551 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| Imaradenant SCHEMBL2320714 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL20392689 | 0.79 | MAP4K4 (0.50) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL2329366 | 0.77 | ADORA2A (0.79) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL2324262 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039109-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | ANKURA TRUST COMPANY, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20210214459-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | ANKURA TRUST COMPANY, LLC | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214459-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NT5E, ENTPD5, ENTPD1 | ADORA2A 19/4885ADORA1 69/4885ADORA2B 79/4885 |
| US-20230039109-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NT5E, ENTPD5, ENTPD1 | ADORA2A 19/4885ADORA1 69/4885ADORA2B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.